Skip to main content
Homepage of ProQR
  • We are ProQR
    • About ProQR Therapeutics
    • Founding story
    • Leadership
    • Careers
      • Vacancies
    • Contact
    • Events
  • Science & Pipeline
    • Pipeline
      • Sepofarsen (CEP290 LCA10)
      • QR-421a (USH2A RP)
      • QR-1123 (RHO RP)
      • QR-504a (TCF4 FECD)
    • Presentations & Publications
    • RNA therapy
      • Axiomer technology
  • Patients & Community
    • Blogs, Stories & News
    • What is a clinical trial?
      • Illuminate Ph2/3 trial (CEP290 LCA10)
      • Brighten pediatric trial (CEP290 LCA10)
      • Stellar Ph1/2 trial (USH2A RP)
      • Aurora Ph1/2 trial (RHO RP)
      • Fuchs Focus Ph1 trial (TCF4 FECD)
    • Inherited retinal diseases
      • Leber congenital amaurosis
      • Retinitis pigmentosa
      • Usher syndrome
    • The importance of genetic testing
      • My Retina Tracker program
    • Eye Connect newsletter
    • Expanded access policy
  • Health Professionals
    • Clinical research
    • Events
    • Expert Eyes newsletter
    • Expert Perspectives series
    • HCP resources
      • IRDs and assessment
      • Patient journey and referral
      • Genetic testing
      • Intravitreal injection
  • Investors & Media
    • Press Releases
    • Events
    • Email alerts
    • Corporate presentation
    • Share performance
    • Financial information
    • Corporate governance
    • Analysts
Press releases

Email alerts

Subscribe for email alerts

Get an email alert every time ProQR issues a press release. Never miss a quarterly report, event announcement, or news update again.

Follow us:

  • Twitter
  • Facebook
  • LinkedIn
  • YouTube
  • SoundCloud
  • Contact
  • Disclaimer
  • Privacy
© 2021 ProQR Therapeutics. All Rights Reserved.